Bringing Precision Medicine to Brain Tumors
Therillume is a clinical-stage neuro-oncology therapeutics company bringing precision medicine to patients with Glioblastoma (GBM) and Neurofibromatosis Types 1 and 2 (NF1 and NF2). Therillume is a human therapeutic company, spinning out from Recombinetics Inc., and leveraging its pioneering precise gene-editing platform and intellectual property to identify, validate and expedite high-quality candidates through clinical development.
Check out our latest publication showing the power of combination therapy for treating Neurofibromatosis Type 1:
https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(23)00166-X
FACING THE FACTS
Glioblastoma (GBM)
Neurofibromatosis Type 1 (NF1)
Seeking investment and strategic partnerships
Reach out today for information on how you can make a difference